Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 600 results for diabetes

  1. In women with type 1 diabetes who are planning to become pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring intermittent capillary blood glucose monitoring?

    Recommendation ID NG3/6 Question In women with type 1 diabetes who are planning to become pregnant, what is the most effective method of

  2. Semaglutide for managing overweight and obesity (TA875)

    Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.

  3. Effectiveness of SGLT2 inhibitors for adults with a urine ACR below 3 mg/mmol: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than 3 mg/mmol?

    clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than...

  4. Referral criteria for the foot protection service and the multidisciplinary foot care service:- When and with what criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?

    multidisciplinary foot care service:- When and with what criteria should people with diabetes be referred to the foot protection service...

  5. Weight management: referral to weight management programmes for obesity (IND220)

    This indicator covers the percentage of patients with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months who have been offered referral to a weight management programme within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM202

  6. Bipolar, schizophrenia and other psychoses: annual BMI recording (IND83)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of BMI in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomesThis indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM16

  7. Cardiovascular disease prevention: statins for people newly diagnosed with hypertension or T2DM (IND162)

    This indicator covers, in patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of more than 20% in the preceding 12 months, the percentage who are currently treated with statins (unless there is a contraindication). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM133

  8. Cardiovascular risk assessment and lipid modification (QS100)

    This quality standard covers identifying and assessing cardiovascular risk in adults (aged 18 and over) and treatment to prevent cardiovascular disease. It describes high-quality care in priority areas for improvement.

  9. How do socioeconomic, environmental, biological and psychosocial factors determine diet and physical activity behaviours and how do they contribute to differences in the risk of developing type 2 diabetes?

    type 2 diabetes? Any explanatory notes(if applicable) None. Source guidance details Comes from guidance Type 2 diabetes...

  10. Teprotumumab for treating thyroid eye disease [ID6432]

    In development [GID-TA11531] Expected publication date: 20 August 2025

  11. What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?

    effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes? Any explanatory notes(if applicable) For a...

  12. The effects of stopping and/or switching drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision?

    drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug...

  13. Bipolar, schizophrenia and other psychoses: 6 physical health checks (IND248)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who, in the preceding 12 months, received all 6 elements of physical health checks for people with severe mental illness. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM232

  14. Inducing labour (NG207)

    This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.

  15. Smoking: smoking status for people with long-term conditions (IND97)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38